Our primary outcome was the measure ’s minimal important difference ( MID ) .
Conclusions In this focused evidence review , the most evidence on key psychometric properties in chronic musculoskeletal pain population s was found for the ODI , RMDQ , SF-36 BPS , NRS , and VAS .
Background Developing successful interventions for chronic musculoskeletal pain requires valid , responsive , and reliable outcome measures .
The Minneapolis VA Evidence -based Synthesis Program completed a focused evidence review on key psychometric properties of 17 self-report measures of pain severity and pain-related functional impairment suitable for clinical research on chronic musculoskeletal pain .
Assessment of pain and activity using an electronic pain diary and actigraphy device in a randomized, placebo-controlled crossover trial of celecoxib in osteoarthritis of the knee.
OBJECTIVE The primary goal was to determine whether a composite measure of pain and activity is a more responsive assessment of analgesic effect than pain alone or activity alone in patients with osteoarthritis ( OA ) of the knee . DESIGN We conducted a r and omized , double-blind , placebo-controlled , 2-period , crossover study of celecoxib vs. placebo in subjects with chronic pain due to knee OA . Patients with knee OA and baseline pain intensity score ≥4 on a 0 - 10 numerical rating scale ( NRS ) before each period were r and omized . Pain endpoints included in-clinic pain score ( 24-hour and 1-week recall ) , daily paper diary pain score , current pain on an electronic pain diary ( each on NRS ) , and WOMAC pain subscale . Activity measures included WOMAC function subscale and actigraphy using a device . Three composite pain-activity measures were prespecified . RESULTS Sixty-three patients were r and omized and 47 completed the study . The WOMAC pain subscale was the most responsive of all five pain measures . Pain-activity composites result ed in a statistically significant difference between celecoxib and placebo but were not more responsive than pain measures alone . However , a composite responder defined as having 20 % improvement in pain or 10 % improvement in activity yielded much larger differences between celecoxib and placebo than with pain scores alone . Actigraphy was more responsive than the WOMAC function scale , possibly due to lower placebo responsiveness . CONCLUSION We have identified composite pain-activity measures that are similarly or more responsive than pain-alone measures in patients with OA . Further research is warranted to determine the optimal method for computing these composites
Our primary outcome was the measure ’s minimal important difference ( MID ) .
Conclusions In this focused evidence review , the most evidence on key psychometric properties in chronic musculoskeletal pain population s was found for the ODI , RMDQ , SF-36 BPS , NRS , and VAS .
Background Developing successful interventions for chronic musculoskeletal pain requires valid , responsive , and reliable outcome measures .
The Minneapolis VA Evidence -based Synthesis Program completed a focused evidence review on key psychometric properties of 17 self-report measures of pain severity and pain-related functional impairment suitable for clinical research on chronic musculoskeletal pain .